Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib + Capecitabine vs Capecitabine in Advanced Breast Cancer
NCT00435409Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2007
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of sunitinib in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Progression Free Survival up to 3 years. Started Feb 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00435409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00435409.